Skip to content

The Role of Ultrasound in COVID-19

The ECHOVID-19 Study - A Prospective Cohort Study Investigating the Acute Effect of COVID-19 on the Heart and Lung by Ultrasound

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04377035
Enrollment
305
Registered
2020-05-06
Start date
2020-03-31
Completion date
2021-03-01
Last updated
2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Brief summary

The study is a prospective clinical cohort study of consecutive patients hospitalized at all hospitals of greater Copenhagen with a laboratory confirmed diagnosis of COVID-19. The investigators aim to examine if echocardiography - both conventional and advanced - can be used to predict which patients will develop acute respiratory distress syndrome (ARDS) or other short-term acute complications, especially focusing on cardiovascular outcomes. In addition, using a novel technique of lung ultrasound (LUS), The investigators aim to analyze specific LUS-findings, and associate them with short-term prognosis and development of ARDS and long-term cardiovascular morbidity and mortality. In all patients included, The investigators aim to examine long-term complications at timepoints: 2, 5 and 10 years of follow-up and examine if echocardiography - alone and in combination with biomarkers - can be used to detect early signs of cardiac complications and predict long-term risk of cardiovascular morbidity and mortality following COVID-19 infection

Interventions

None listed

Sponsors

University Hospital, Gentofte, Copenhagen
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* All patients hospitalized at hospitals of greater Copenhagen area and Zealand with a laboratory confirmed diagnosis of COVID-19 \> 18 years of age.

Exclusion criteria

* Persons not able to cooperate * Persons unable to understand and sign informed consent

Design outcomes

Primary

MeasureTime frame
Incident hypoxic respiratory failure during hospitalization and a confirmed COVID-19 diagnosis2.5 months
In-hospital mortality during hospitalization and a confirmed COVID-19 diagnosis2.5 months
Incident ARDS (Adult Respiratory Distress Syndrome) and intensive care unit admission during hospitalization and a confirmed COVID-19 diagnosis2.5 months

Secondary

MeasureTime frame
Incident stroke after hospital admission with a confirmed COVID-19 diagnosis at follow-up2.5 months to 10 years
Incident cardiac arrest during hospitalization and a confirmed COVID-19 diagnosis2.5 months
Incident myocardial infarction after hospital admission with a confirmed COVID-19 diagnosis at follow-up2.5 months to 10 years
Incident heart failure after hospital admission with a confirmed COVID-19 diagnosis at follow-up2.5 months to 10 years
Incident pulmonary embolism during hospitalization and a confirmed COVID-19 diagnosis2.5 months
Death from any cause after hospital admission with a confirmed COVID-19 diagnosis at follow-up2.5 months to 10 years

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 22, 2026